How does specialised formula compare to breast milk for premature infants?

Question

Accepted Answer

Specialized Infant Formula vs. Breast Milk for Premature Infants

A jury has found that Abbott Laboratories' specialized formula for premature infants caused a severe bowel disease in an Illinois girl, leading to a US$495 million damages award. This case highlights ongoing legal and medical discussions about the risks and benefits of specialized formulas compared to breast milk for premature infants. The lawsuits central to this issue allege that companies failed to adequately warn healthcare providers that their formulas may increase the risk of necrotizing enterocolitis (NEC) in premature newborns.
Allegations of Inadequate Warnings for Specialized Formulas

The core of the legal claims against manufacturers like Abbott Laboratories centers on the alleged failure to warn about the potential risks of NEC associated with their specialized infant formulas. Plaintiffs contend that these companies did not inform doctors that infants fed with these formulas face a greater risk of NEC compared to those who receive breast milk, donor milk, or human milk-derived formula. This alleged lack of transparency is a key factor in the jury's decision, which awarded US$95 million in compensatory damages and US$400 million in punitive damages to the plaintiff in the Illinois case.
Abbott's Defense of Specialized Formula Necessity

Abbott Laboratories maintains that specialized formulas and fortifiers are often among the sole available options for feeding premature infants. The company argues that these products can be necessary and even life-saving for babies born prematurely. In the context of the trial, Abbott's defense suggested that the plaintiff's long-term injuries might have stemmed from birth trauma rather than the formula, and acknowledged that while mother's milk can reduce NEC risk, specialized formulas remain a critical option for infant nutrition.
Understanding Necrotizing Enterocolitis (NEC)

Necrotizing enterocolitis (NEC) is a serious gastrointestinal disease that primarily affects premature newborns, causing the death of bowel tissue. This condition carries a significant fatality rate, estimated to be between 15% and 40%. The case involving Abbott’s formula resulted in the infant developing NEC, leading to irreversible neurological damage and a lifelong need for care, even though the child survived the initial illness.
Broader Legal Landscape and Professional Perspectives

The trial against Abbott is one of close to 1,000 lawsuits filed against both Abbott and Reckitt Benckiser, the maker of Enfamil formula, concerning NEC. While these legal actions focus on the risks of specialized formulas, some medical organizations, such as the NEC Society, have voiced concerns about the litigation. They argue that feeding decisions for vulnerable infants should be made at the bedside by medical professionals, rather than being determined in courtrooms. A previous trial against Reckitt in March resulted in a US$60 million jury verdict, which the company is currently appealing.

Reading history

Hide →

This history is cleared when the page is closed.

How does specialised formula compare to breast milk for premature infants?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends